trending Market Intelligence /marketintelligence/en/news-insights/trending/WKHjtfsGv9Rfi3h05CaNIg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Akcea seeks EMA approval for rare disorder drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Akcea seeks EMA approval for rare disorder drug

Akcea Therapeutics Inc. filed an application with the European Medicines Agency, seeking approval for a treatment of a rare genetic disorder.

Volanesorsen is meant for patients with the familial chylomicronemia syndrome which results in abdominal pain and potentially fatal bouts of pancreatitis, the inflammation of the pancreas.

Akcea, a unit of Ionis Pharmaceuticals Inc., will also file applications for its drug in Canada and the U.S. in September.